Evidence map›Paper›PMID 35620255›Full record

ArticleClinical case reports2022

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management.

Olga Benitez Hidalgo, M Fernanda Martinez Garcia, Agustin Bescos Cabestre, Juan Carlos Juarez Gimenez, Mercedes Gironella Mesa, Francesc Bosch Albareda

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Olga Benitez HidalgoHematology Department Experimental Hematology Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.ORCID https://orcid.org/0000-0002-2883-9049
M Fernanda Martinez GarciaHematology Department Experimental Hematology Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.
Agustin Bescos CabestreNeurosurgery Department- Spine Unit Hospital Universitari Vall d'Hebron Barcelona Spain.
Juan Carlos Juarez GimenezHospital Pharmacy Department Hospital Universitari Vall d'Hebron Barcelona Spain.
Mercedes Gironella MesaHematology Department Experimental Hematology Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.
Francesc Bosch AlbaredaHematology Department Experimental Hematology Vall d'Hebron Institute of Oncology (VHIO) Hospital Universitari Vall d'Hebron Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.
Hebron University · PSVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extended half-life FIX (EHL-FIX) concentrates have been developed with the purpose of reducing the frequency of infusions in patients with severe or moderate hemophilia B. We describe the case of a 63-year-old patient with severe hemophilia B (sHB) treated with FIX-Fc fusion protein (rFIXFc) who underwent neurosurgery.

Indexed as

anesthesiahaemophilia BhematologyneuosurgerypharmacologyrFIX‐Fc

Identifiers

PMID35620255
PMCPMC9127245
OpenAlexW4281390987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.